Cancer vaccine prevents deadly melanoma from returning or spreading in landmark trial

An experimental skin cancer vaccine significantly reduced the risk of melanoma returning or spreading in a late-stage clinical trial from Merck and Moderna.

The results mark the first positive Phase 3 trial of an mRNA-based personalized cancer therapy, according to the companies.

Known as INTerpath-001, the study evaluated 1,137 patients globally who had surgery to remove high-risk (Stage IIB through Stage IV) melanoma. Patients were randomly assigned to receive either Keytruda, plus the personalized vaccine...